

No.: 16600

Client No.:

Re No.: 16051-10US

**OGILVY
RENAULT**

LLP/SENCRL, s.r.l.

Facsimile**RECEIVED
CENTRAL FAX CENTER****MAY 02 2007****Confidentiality Message**

This communication sent by facsimile is confidential, may be privileged and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If the addressee cannot be reached or is unknown to you, please destroy this message and all copies. Thank you.

Number of pages including this cover sheet: 9

Date: May 2, 2007

From: Christian Cawthorn / Demian Barbas
Our File No. 16051-10US CC/DBB/jrl

Telephone: (514) 847-4256 / 4867

Direct Fax: (514) 288-8389

E-Mail: ccawthorn@ogilvyrenault.com
dbarbas@ogilvyrenault.com

| To | Company - City | Fax |
|-------------------------|--------------------------------|----------------|
| Commissioner of Patents | U.S. Patent & Trademark Office | 1-571-273-8300 |

Response to Office Action
Due May 5, 2007

Applicants: Andrew VAILLANT et al.

Serial Number: 10/661,355

Filing date: September 12, 2003

For: METHOD FOR IDENTIFYING ANTIVIRAL OLIGONUCLEOTIDES

Art Unit: 1648

Examiner: Sharon L. HURT

Barristers & Solicitors,
Patent Agents & Trade-mark AgentsSuite 1600
1981 McGill College Avenue
Montréal, Québec H3A 2Y3
CanadaTelephone (514) 847-4747
Fax (514) 288-8389

ogilvyrenault.com

File No. 16051-10US CC/DBB/jrl

IN THE UNITED STATES PATENT AND TRADEMARK OFFICERECEIVED
CENTRAL FAX CENTER
MAY 02 2007

Applicants: Andrew VAILLANT et al.
Serial Number: 10/661,355
Filing date: September 12, 2003
For: METHOD FOR IDENTIFYING ANTIVIRAL OLIGONUCLEOTIDES
Art Unit: 1648
Examiner: Sharon L. HURT
Agent: Cawthorn, Christian (514) 847-4256

RESPONSE TO OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia
22313-1450

Sir:

In response to the Office Action dated February 5, 2007, in connection with the above-identified patent application, please consider the following amendment and remarks.

AMENDMENTS TO THE SPECIFICATION

Amendments to the Specification begin on page 2 of this paper.

AMENDMENTS TO THE CLAIMS

Amendments to the claims are reflected in the listing of claims which begins on page 3 of this paper.

REMARKS

Remarks begin on page 7 of this paper.